How effective is the Pfizer-BioNtech vaccine against the South African coronavirus strain? 

February 18, 2021 11:55 AM GMT | By Team Kalkine Media
 How effective is the Pfizer-BioNtech vaccine against the South African coronavirus strain? 

Summary

  • A lab study has found that Pfizer-BioNtech vaccine could be less impactful on South African strain.
  • The vaccine had two-thirds less neutralising impact on antibodies against the South African strain.
  • Though the companies said they did not have any conclusive proof yet.

 

A lab study has revealed that the Pfizer Inc (LON:0Q1N) and BioNTech SE’s (LON:0A3M) Covid-19 vaccine candidate had two-thirds less neutralising impact on antibodies against the South African strain of coronavirus. 

It, however, could not be established whether the reduction would make the vaccine unproductive against the South African strain, as there is still no benchmark to decide how much antibodies are necessary for protection against the virus strain.  

Copyright © 2020 Kalkine Media Pty Ltd.

 

 

 

The study, conducted by Pfizer and BioNTech and researchers from the University of Texas Medical Branch at Galveston, was published in the New England Journal of Medicine. The researchers have said blood samples collected from vaccinated patients displayed notable levels of neutralising impact on antibodies against the South Africa strain.  

 

Also read: A race against COVID-19: Meet five global vaccine developers in the fray 

 

The study also said there was not enough conclusive evidence to show from trials conducted on people that the variant is potent enough to reduce vaccine protection. 

 

What scientist found 

Scientists from the companies and the University of Texas Medical Branch (UTMB) created a virus containing the same mutations found on the spike portion of the much more contagious strain of coronavirus. The spike portion is used by the virus to enter human cells and hence targeted by vaccines.  

 

This virus was tested on blood samples collected from vaccinated people and the results showed that neutralising impact of the vaccine on antibodies reduced by two-thirds, in comparison to the vaccine’s impact on the more common strain of the virus. The companies are, however, confident that the vaccine would work against the South African strain of the virus. 

 

Also read: Better than injection? All about nasal COVID-19 vaccines in the pipeline 

 

UTMB professor and the study’s co-author Pei-Yong Shi said that more research was required to understand whether the vaccine is effective enough against the South African variant. Shi said that more clinical trials were required to conclude what could be the optimum levels of antibodies necessary for protection.  

 

Another study conducted by researchers from the National Institute of Allergy and Infectious Diseases and Moderna Inc (LON:0A45) examined how effective the company’s vaccine was against the South African strain in a lab. This study also found a crucial fall in coronavirus-fighting antibodies. Neutralising antibodies decreased six times, as against the levels produced against previous strains of the virus. 

 

Fight continues 

Despite new impediments, vaccine companies have been relentlessly working for a smooth rollout drive globally. In a separate development, Pfizer and BioNTech announced that they would be supplying the European Union with 200 million more doses of their Covid-19 vaccine. 

The agreement for fresh supplies is over and above the 300 million vaccine doses that have already been finalised. The fresh supplies would be delivered this year, of which about 75 million does are expected in the second quarter.  

 

Also read: AstraZeneca (LON:AZN) tries to clear the air over vaccine shortage with EU 

 

Pfizer CEO Albert Bourla said that the company would be expanding manufacturing capacity to support the growing demand for vaccine rollouts in the EU and other parts of the world. BioNTech CEO Ugur Sahin said that the company built up its manufacturing networks and is ready to start production in its new plant in Marburg, Germany. 

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next